Trial Profile

Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIV

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 31 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir (Primary) ; Abacavir; Cobicistat; Darunavir; Lamivudine; Lamivudine/zidovudine; Rilpivirine; Tenofovir alafenamide; Tenofovir disoproxil fumarate; Zidovudine
Indications HIV-1 infections
Focus Adverse reactions

Most Recent Events

25 Jul 2023 Status changed from recruiting to completed.
11 Jan 2021 Planned End Date changed from 1 Mar 2021 to 30 Jan 2022.
11 Jan 2021 Planned primary completion date changed from 1 Jan 2021 to 17 Sep 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com